

Nothing herein is to be disclosed in any way without the prior express written permission of W. L. Gore & Associates, Inc.

**Observational Study of the GORE® TAG® Thoracic Endoprosthesis in the treatment of diseases of the thoracic aorta**

Protocol number: FPR 12-03

Protocol date: 21-SEP-2015

NCT number: NCT02266342

W. L. Gore & Associates, Inc.  
Medical Products Division

		Gore-TAG_SAP_V2.2
		<b>Sponsor:</b> W.L. GORE & ASSOCIATE
		<b>Device:</b> GORE TAG
		<b>Protocol Nr:</b> FRP 1203

## STATISTICAL ANALYSIS PLAN

### Observational Study of the GORE® TAG® Thoracic Endoprosthesis in the treatment of diseases of the thoracic aorta

#### Statistical Analysis Plan

Versions	Date	Documents used / Comments	Author	Validation
Version 2.2	24/02/2017	- Gore-TAG_SAP_V2.1 (secondary procedures = re-interventions)		
Version 2.1	31/03/2016	- Gore-TAG_SAP_V2.0 + Comments from WL Gore following SAR V2.0 review		
Version 2.0	21/03/2016	- Gore-TAG_SAP_V1.3 + Comments from WL Gore following SAR V1.0 review + Titles/wording updates to be consistent with the English version of the CRF		
Version 1.3	01/12/2015	- Gore-TAG_SAP_V1.2 + Comments from WL Gore (30NOV2015) + Call (30NOV2015)		
Version 1.2	25/11/2015	- Gore-TAG_SAP_V1.1 + Addition of life-threatening emergency definition		
Version 1.1	02/11/2015	- Gore-TAG_SAP_V1.0 + Addition of derived criteria calculation		
Version 1.0	22/10/2015	- Gore-TAG_SAP_V0.4 + Comments from WL Gore (06OCT2015) + mails from W L Gore on secondary endpoints (07, 08, 09 and 12OCT2015)		

Sponsor:

W.L. Gore & Associés S.A.R.L.

8 place des Vins de France

75012 PARIS

France

# STATISTICAL ANALYSIS PLAN

Gore-TAG\_SAP\_V2.2

**Sponsor:** W.L. GORE & ASSOCIATE

**Device:** GORE TAG

**Protocol Nr:** FRP 1203

Versions	Date	Documents used / Comments	Author	Validation
Version 0.4	20/08/2014	- Gore-TAG_SAP_V0.3 + Comments from WL Gore (19AUG2015)		
Version 0.3	13/08/2015	- Gore-TAG_SAP_V0.2 + Comments from WL Gore (13AUG2015)		
Version 0.2	17/07/2015	- Gore-TAG_SAP_V0.1 + List of tables, graphs and listings + Layout of table		
Version 0.1	08/07/2015	- PROT 14-10-03 FPR 12-03 FR final EN-US - Annotated CRF		

## CONFIDENTIEL / CONFIDENTIAL

Toute reproduction ou distribution, totale ou partielle, de ce document, sans autorisation préalable de MedPass International est interdite.  
Reproduction and distribution of this document, in whole or in part, is strictly forbidden without prior authorization from MedPass International.

## STATISTICAL ANALYSIS PLAN


Gore-TAG\_SAP\_V2.2  
Sponsor: W.L. GORE & ASSOCIATE  
Device: GORE TAG  
Protocol Nr: FRP 1203

## SIGNATURE PAGE

### OBSERVATIONAL STUDY OF THE GORE® TAG® THORACIC ENDOPROSTHESIS IN THE TREATMENT OF DISEASES OF THE THORACIC AORTA

Version 2.2

#### W.L. GORE & ASSOCIÉS

Name	Position	Date	Signature
Abe Letter	Clinical Biostatistician	27-FEB-2017	
Alexandre Figard	Clinical Study Manager	27-FEB-2017	

#### CONFIDENTIEL / CONFIDENTIAL

Toute reproduction ou distribution, totale ou partielle, de ce document, sans autorisation préalable de MedPass International est interdite.  
Reproduction and distribution of this document, in whole or in part, is strictly forbidden without prior authorization from MedPass International.

# STATISTICAL ANALYSIS PLAN

## TABLE OF CONTENTS

<b>List of abbreviations and definition of terms .....</b>	<b>5</b>
<b>1. Overview.....</b>	<b>6</b>
1.1. Study Objective.....	6
1.2. Study Design.....	6
1.3. Study Plan.....	6
1.3.2. Study duration.....	6
1.3.3. Study Device.....	6
1.3.4. Study Assessments.....	7
<b>2. Statistical methods.....</b>	<b>7</b>
2.1. General Statistical Considerations .....	7
2.1.1. Descriptive Statistics in Summary Tables.....	7
2.1.2. Inferential Analysis.....	7
2.1.3. Handling Missing Data .....	7
2.1.4. Data Listings .....	8
2.3. Analysis Sets .....	8
2.3.1. Definition of patient populations .....	8
2.4. Statistical Analyses .....	8
2.4.1. Patient Disposition.....	8
2.4.2. Patient Characteristics.....	9
2.4.3. Endpoints Analyses.....	9
2.4.4. Safety Analyses.....	10
2.5. Derived Criteria Calculation .....	10
<b>3. Statistical Software .....</b>	<b>11</b>
<b>4. Statistical tables, Graphs and Listings (Table of contents).....</b>	<b>11</b>
4.1. Statistical Tables .....	11
4.2. Graphs.....	13
4.3. Listings.....	14
<b>5. Layout of the statistical tables .....</b>	<b>15</b>
5.1. Continuous variables.....	15
5.1.1. No group (Type 1) .....	15
5.1.1. With groups (Type 2).....	15
5.2. Categorical variables.....	15
5.2.1. No group (Type 3) .....	15
5.2.2. With groups (Type 4).....	15
5.3. Others.....	16
5.3.1. Several variables or variables with more than one modality by patient (Type 5) .....	16
5.3.2. Conditional variables (Type 6) .....	16
5.3.1. Conditional variables with groups (Type 7).....	16
5.3.1. Adverse events (Type 8) .....	17
5.3.2. Survival curve (Type 9) .....	18

## CONFIDENTIEL / CONFIDENTIAL

	<b>STATISTICAL ANALYSIS PLAN</b>	Gore-TAG_SAP_V2.2 TAG Registry Page 5/18
--	----------------------------------	--

## LIST OF ABBREVIATIONS AND DEFINITION OF TERMS

AE	Adverse Event
CI	Confidence Interval
CRF	Case Report Form
CT-scan	Computed Tomography scan
FUP	Follow-up
LPPR	Liste des Produits et Prestations Remboursables (List of Reimbursable Products and Services)
MRI	Magnetic resonance imaging
SAP	Statistical Analysis Plan

## CONFIDENTIEL / CONFIDENTIAL

Toute reproduction ou distribution, totale ou partielle, de ce document, sans autorisation préalable de MedPass International est interdite.  
Reproduction and distribution of this document, in whole or in part, is strictly forbidden without prior authorization from MedPass International.

# STATISTICAL ANALYSIS PLAN

## 1. OVERVIEW

This statistical analysis plan (SAP) describes the planned statistical analyses of the data collected in the course of the observational study of the GORE® TAG® thoracic endoprosthesis in the treatment of diseases of the thoracic aorta.

This SAP provides additional details concerning the statistical analyses outlined in the protocol (version dated 21SEP2015). The purpose of the SAP is to ensure the credibility of the study findings by pre-specifying the statistical approaches to the analysis of study data.

### 1.1. Study Objective

The objective of this study is to evaluate the usefulness of the technique in terms of efficacy and safety of use of the GORE® TAG® and Conformable GORE® TAG® thoracic endoprosthesis at 5 years, on a cohort of patients representative of the population treated in real life conditions.

### 1.2. Study Design

This study is an observational, prospective, multicenter, non-randomized, single-arm and open-label which 160 patients will be enrolled from approximately 30 investigational French sites.

### 1.3. Study Plan

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

#### 1.3.2. Study duration

The duration of the study will be determined by the duration of recruiting 160 consecutive patients within 30 potential investigation centers.

- Enrollment period for the 160 patients: 24 months
- Follow-up period for each patient: 5 years
- Total duration of the study: 7 years (84 months)

#### 1.3.3. Study Device

The study devices are the GORE® TAG® and Conformable GORE® TAG® thoracic endoprosthesis including any newer models [REDACTED]

## STATISTICAL ANALYSIS PLAN

### 1.3.4. Study Assessments

The following flowchart applies to the study:

Data	CRF Pré-op.	CRF Treatment	CRF Post-op.	CRF Follow-up	CRF AE	CRF Re-intervention	CRF Study Exit
Consent	X						
Eligibility criteria	X						
Imaging tests	X		X	X			
Clinical history	X						
Assessment of disease(s) and diagnosis(es)	X						
Implantation		X					
Information on the device used		X					
Post-operative assessment			X				
Post-operative follow-up at D1-D30, 1, 2, 3, 4 and 5 years				X			
Onset of complications		X	X	X	X		
Repeat vascular intervention						X	
Surgical conversion						X	X
Lost to follow-up							X
Death					X		X

## 2. STATISTICAL METHODS

### 2.1. General Statistical Considerations

#### 2.1.1. Descriptive Statistics in Summary Tables

- Continuous variables will be summarized using standard quantitative statistics: number of non-missing observations, mean, standard deviation, median, quartiles and range (minimum and maximum observed values). The number of missing observations will also be specified.
- Categorical variables will be summarized using classical frequency statistics: number of non-missing observations and percentages by categories. Percentages will be calculated on the number of non-missing observations and will be displayed using one decimal, the corresponding bilateral 95% CI will be presented if appropriate. The number of missing observations will also be specified.

#### 2.1.2. Inferential Analysis

Differences between groups in survival analysis will be addressed by the log-rank test.

#### 2.1.3. Handling Missing Data

No replacement of missing data is planned.

If a patient interrupts the study before the end of study, he/she will be considered as missing from his/her last follow-up.

Patients will be considered as censored at the date of the last observation in survival analyses.

## CONFIDENTIEL / CONFIDENTIAL

## STATISTICAL ANALYSIS PLAN

### 2.1.4. Data Listings

Patient data listings will be selected data supportive of summary statistical tables, including derived/calculated data from statistical process. These key data listings will be performed on selected analysis sets according to the focus of the listings.



### 2.3. Analysis Sets

#### 2.3.1. Definition of patient populations

2 populations will be defined:

- The “included” population will include all patients enrolled in the study.
- The Per Protocol (PP) population will include all “included” patients for whom the GORE® TAG® and Conformable GORE® TAG® thoracic endoprosthesis were introduced through surgical or percutaneous approach, and who fulfill the eligibility criteria.

### 2.4. Statistical Analyses

All analyses will be conducted on the PP population.

The “included” populations defined in section 2.3.1 will only be used to list the patients who do not fulfill the eligibility criteria.

#### 2.4.1. Patient Disposition

The following items will be presented:

- The number of included and PP patients (globally and by center) as well as a listing of non-included patients and patients excluded from the PP population
- A study flowchart table will be presented on the PP population and the reasons of interruption will be specified.
- Study duration:
  - The total study duration (between procedure and study exit) will be presented globally.
  - The study follow-up duration (between procedure and the last available follow-up) will also be presented in intermediary report(s).

**CONFIDENTIEL / CONFIDENTIAL**

Toute reproduction ou distribution, totale ou partielle, de ce document, sans autorisation préalable de MedPass International est interdite.  
Reproduction and distribution of this document, in whole or in part, is strictly forbidden without prior authorization from MedPass International.

## STATISTICAL ANALYSIS PLAN

### 2.4.2. Patient Characteristics

Descriptive statistical data will be used to draw up a recapitulation of PP patients at baseline, procedure and follow-up.

#### 2.4.2.1. Baseline

- Demographics
- Medical condition (Medical history / risks factors, patient symptoms)
- Patient participation in another W.L. Gore study
- Life-threatening emergency
- Main indication for implantation
- Dissections and trauma patients characteristics
- Procedure planning

#### 2.4.2.2. Procedure

- Implantation parameters
- Procedure evaluation and results
- Device used
- Imaging abnormalities
- Time spent in ICU

#### 2.4.2.3. Follow-up

The following items will be presented at each visit:

- Measurements and dissections characteristics
- Imaging abnormalities

### 2.4.3. Endpoints Analyses

#### 2.4.3.1. Primary Analysis

The primary endpoint is the all-cause mortality rate over the long term, which is 5 years.

The 5-year mortality is defined for all deaths occurring between the time of surgery when the endoprosthesis was inserted into the arterial access and the last follow-up visit at 5 years.

It will be presented as a categorical variable (with the corresponding 95% bilateral CI), overall and by visit, and described over time by a survival curve as per the Kaplan-Meier method together with the associated estimators.

The primary endpoint will also be analyzed depending on the life-threatening emergency and by main indication for implant (aneurysm, dissection, ulcer and trauma).

#### 2.4.3.2. Secondary Analyses

The secondary endpoints for assessing the usefulness of the technique will be:

- The exclusion rate of the aneurysm, the false lumen, the penetrating aortic ulcer or rupture site, with no type I or III endoleak (overall and by main indication for implantation)

It will be presented as categorical variables (with the corresponding 95% bilateral CI) by time-point, starting at 30 days.

- The rate of neurological complications
- The rate of cardiac, renal and pulmonary complications
- The rate of device-related complications
- The rate of surgical conversion
- The rate of secondary procedures (re-interventions)
- The rate of mortality related to the disease

#### CONFIDENTIEL / CONFIDENTIAL

## STATISTICAL ANALYSIS PLAN

They will be presented as categorical variables (with the corresponding 95% bilateral CI) by time-point and described over time by a survival curve as per the Kaplan-Meier method together with the associated estimators.

### 2.4.4. Safety Analyses

The safety will also be assessed by the analysis of secondary procedures and adverse events.

#### 2.4.4.1. Secondary procedures

- Secondary procedure rate and reasons
- Endovascular/surgical treatment details
- Imaging abnormalities

#### 2.4.4.2. Adverse events

The adverse events analysis will present the number of event of each following category, the number of patients with at least one event of each category and the corresponding percentage:

- Adverse events (overall, serious, device-related and procedure-related)
- Reasons of SAE seriousness.

## 2.5. Derived Criteria Calculation

- A patient will be considered as fulfilling the eligibility criteria if:
  - Inclusion criterion 1 is ticked YES
  - Inclusion criterion 2 is ticked YES or date of informed consent is filled
  - Inclusion criterion 3 is ticked YES
  - Exclusion criterion 1 is ticked NO
  - Exclusion criterion 2 is ticked NO
- Total study duration will be calculated as:  
Total study duration = study exit date - procedure date +1  
If the procedure date is not available, the baseline date will be used instead.
- Study follow-up duration will be calculated as:  
Study follow-up duration = last FUP date available - procedure date +1  
If the procedure date is not available, the baseline will be used instead.  
If the visit date is not available, the corresponding last imaging date will be used instead.
- Body Mass Index will be calculated as:  
 $BMI = \text{weight (kg)} / (\text{height (m)})^2$
- Derived criterion “life-threatening emergency” will be derived as follows:
  - if vital urgency specify is “Aortic rupture” then life-threatening emergency will be “Yes: Aortic rupture”
  - else if vital urgency specify is “Dissection complicated by malperfusion” then life-threatening emergency will be “Yes: Dissection complicated by malperfusion”
  - else if vital urgency specify is “Other” then life-threatening emergency will be “Yes: Other”
  - else if vital urgency is “No” then life-threatening emergency will be “No”
- Derived criterion “procedure duration” will be calculated as follows:  
Procedure duration = procedure end time – procedure start time
- Derived criterion “exclusion of the aneurysm without endoleak” will be defined as follows:  
No maximum diameter of the aneurysm sac increase > 5 mm (compared to 1<sup>st</sup> post-op exam) and no type I or type III endoleak

## CONFIDENTIEL / CONFIDENTIAL

## STATISTICAL ANALYSIS PLAN

- Derived criterion "exclusion of the false lumen without endoleak" will be defined as follows:  
"Exclusion of the main entry of the dissection" will be YES if:
  - no false lumen perfusion type Ia, Ib, III is ticked
  - and "Incorrect Deployment" is not ticked or "false lumen perfusion through a tear proximal to the device in an untreated segment (not an endoleak)" is not ticked
  - and "Status of false lumen located opposite the treated part of the aorta" is "Complete thrombosis"
 If the perfusion status is unknown or if the false lumen thrombosis status is unknown then "exclusion of the false lumen without endoleak" will be missing.
- Derived criterion "exclusion of the penetrating aortic ulcer without endoleak" will be defined as follows:  
No maximum aortic diameter of the ulcer increase > 5 mm (compared to 1<sup>st</sup> post-op exam) and no type I or type III endoleak
- Derived criterion "exclusion of the rupture site without endoleak" will be defined as follows:  
No type I or type III endoleak
- Mortality from thoracic disease is defined as any death occurring as a result of complication of aortic disease (rupture, conversion, etc.) or following any surgery intended to treat the aortic disease. It will be derived as follows:
  - If the death occurs within 30 days after the initial procedure or any re-intervention or
  - If the death is related to the disease
 Then mortality from thoracic disease will be "YES"
- An adverse event (or any other parameter that is not reported in a follow-up CRF) will be considered as having occurred
  - "at 1 month" if it occurs between the procedure (included) and 30 days after the procedure
  - "at 1 year" if it occurs between the procedure (included) and 365 days after the procedure
  - "at 2 year" if it occurs between the procedure (included) and 731 days after the procedure
  - "at 3 year" if it occurs between the procedure (included) and 1096 days after the procedure
  - "at 4 year" if it occurs between the procedure (included) and 1461 days after the procedure
  - "at 5 year" if it occurs between the procedure (included) and 1826 days after the procedure

### 3. STATISTICAL SOFTWARE

All statistical outputs (summary tables, data listings and graphs) will be generated using SAS® version 9.4 or later.

### 4. STATISTICAL TABLES, GRAPHS AND LISTINGS (TABLE OF CONTENTS)

#### 4.1. Statistical Tables

##### Patient Disposition

Table 1: Number of PP patients overall and by site (Type 4)

Table 2: Study flowchart and study exit reasons (Type 6)

Table 3: Study durations (days) (Type 1)

##### Patient Characteristics

###### Baseline

Table 4: Age at surgery (years) (Type 1)

Table 5: Sex (Type 3)

#### CONFIDENTIEL / CONFIDENTIAL

## STATISTICAL ANALYSIS PLAN

Table 6: Weight (kg), Height (cm) and BMI (kg/m<sup>2</sup>) (Type 1)  
 Table 7: Medical history / risks factors (Type 6)  
 Table 8: ASA classification (Type 3)  
 Table 9: Patient symptoms related to the disease at hospitalization time (Type 6)  
 Table 10: Patient participation in another W.L. Gore study (Type 3)  
 Table 11: Life-threatening emergency (Type 6)  
 Table 12: Main indication for implantation (Type 6)  
 Table 13: Initial evaluation characteristics for dissection patients (Type 3)  
 Table 14: Initial dissection malperfusion details (Type 6)  
 Table 15: Injury severity of trauma patients (Type 3)  
 Table 16: Glasgow coma scale of trauma patients (Type 1)  
 Table 17: Diameter of the aortic proximal neck (mm) and length of the proximal fixation (mm) (Type 1)  
 Table 18: Characteristic of the proximal neck (Type 3)  
 Table 19: Maximum diameter of the aneurysm/dissection/ulcer (mm) (Type 1)  
 Table 20: Diameter of the distal neck (mm) and length of the distal fixation (mm) (Type 1)  
 Table 21: Characteristic of the distal neck (Type 3)  
 Table 22: Minimal diameter of the main vascular access (mm) (Type 1)  
 Table 23: Significant calcification of the main vascular access (Type 3)  
 Table 24: Mural thrombus and/or calcification in the aortic necks > 50% of the circumference (Type 6)

### *Procedure*

Table 25: Surgeon specialty (Type 3)  
 Table 26: Duration of procedure (min) (Type 1)  
 Table 27: Thoracic endoprosthesis access (Type 5)  
 Table 28: Type of anesthesia used (Type 3)  
 Table 29: Total volume of contrast media used (mL) and total time of exposition to radiation (min) (Type 1)  
 Table 30: Number of devices used per patient (Type 1)  
 Table 31: Successful deployment of endoprosthesis and failure details (Type 6)  
 Table 32: Additional procedure(s) conducted before/during the endovascular surgery (Type 3)  
 Table 33: Imaging abnormalities observed following the procedure (Type 6)  
 Table 34: False lumen perfusion following treatment for dissection (Type 5)  
 Table 35: Persistent endoleak details following the procedure (Type 6)  
 Table 36: Migration details (deployment inaccuracy) identified following the procedure (Type 6)  
 Table 37: Extent of the migration (deployment inaccuracy) identified following the procedure (Type 1)  
 Table 38: Stay in Intensive Care Unit (hours) (Type 1)

### *Follow-up*

Table 39: Maximum diameter of the aneurysm/dissection/lesion (mm) and total length of treatment of the aorta (mm) – by visit (Type 2)  
 Table 40: Dissections characteristics - by visit (Type 4)  
 Table 41: Imaging abnormalities observed - by visit (Type 4)  
 Table 42: Dissection false lumen perfusion characteristics - by visit (Type 7)  
 Table 43: Endoleak details - by visit (Type 7)  
 Table 44: Migration details - by visit (Type 7)

### CONFIDENTIEL / CONFIDENTIAL

# STATISTICAL ANALYSIS PLAN

Gore-TAG\_SAP\_V2.2

TAG Registry

Page 13/18

Table 45: Extent of the migration - by visit (Type 2)

## Endpoints Analyses

### Primary Analysis

Table 46: Mortality – by time point (Type 4)

Table 47: Mortality by life-threatening emergency – by time point (Type 4)

Table 48: Mortality by main indication for implantation – by time point (Type 4)

### Secondary Analyses

Table 49: Rate of exclusion of aneurysm, false lumen, penetrating aortic ulcer or rupture site, with no type I or III endoleak - by time point (Type 4)

Table 50: Rate of exclusion of aneurysm with no type I or III endoleak - by time point (Type 4)

Table 51: Rate of exclusion of false lumen with no type I or III endoleak - by time point (Type 4)

Table 52: Rate of exclusion of penetrating aortic ulcer with no type I or III endoleak - by time point (Type 4)

Table 53: Rate of exclusion of rupture site, with no type I or III endoleak - by time point (Type 4)

Table 54: Neurological complications rate - by time point (Type 4)

Table 55: Cardiac, renal and pulmonary complications rate - by time point (Type 4)

Table 56: Device-related complications rate - by time point (Type 4)

Table 57: Surgical conversion rate - by time point (Type 4)

Table 58: Secondary procedures rate - by time point (Type 4)

Table 59: Mortality rate related to the disease - by time point (Type 4)

## Safety

### Secondary procedures

Table 60: Secondary procedures rate (Type 3)

Table 61: Reasons of secondary procedures (Type 6)

Table 62: Endovascular/Surgical treatment (secondary procedures) (Type 5)

Table 63: Imaging abnormalities observed following secondary procedures (Type 3)

Table 64: False lumen perfusion following secondary procedures - by visit (Type 7)

Table 65: Endoleak details following secondary procedures - by visit (Type 7)

### Adverse events

Table 66: Adverse events (Type 8)

Table 67: Reasons of SAE seriousness (Type 6)

## 4.2. Graphs

Graph 1: Mortality survival analysis (Type 9)

Graph 2: Mortality by life-threatening emergency - survival analysis (Type 9)

Graph 3: Mortality by main indication for implantation survival analysis (Type 9)

Graph 4: Neurological complications survival analysis (Type 9)

Graph 5: Cardiac, renal and pulmonary complications survival analysis (Type 9)

Graph 6: Device-related complications survival analysis (Type 9)

Graph 7: Surgical conversion survival analysis (Type 9)

Graph 8: Secondary procedures survival analysis (Type 9)

Graph 9: Mortality related to the disease survival analysis (Type 9)

## CONFIDENTIEL / CONFIDENTIAL

Toute reproduction ou distribution, totale ou partielle, de ce document, sans autorisation préalable de MedPass International est interdite.  
Reproduction and distribution of this document, in whole or in part, is strictly forbidden without prior authorization from MedPass International.

	<b>STATISTICAL ANALYSIS PLAN</b>	Gore-TAG_SAP_V2.2 TAG Registry Page 14/18
--	----------------------------------	---

#### **4.3. Listings**

##### **Patient Disposition**

Listing 1: Reasons of non-inclusion in the study or exclusion from PP population  
 Listing 2: Patient follow-up, study durations and reasons of study exit and

##### **Patient Characteristics**

###### *Baseline*

Listing 3: Demographics  
 Listing 4: Medical history / risks factors  
 Listing 5: Patient symptoms related to the disease at hospitalization time  
 Listing 6: Patient participation in another W.L. Gore study  
 Listing 7: Life-threatening emergency and main indication for implantation  
 Listing 8: Initial evaluation characteristics for dissection patients  
 Listing 9: Injury severity of trauma patients  
 Listing 10: Procedure planning

###### *Procedure*

Listing 11: Implantation parameters  
 Listing 12: Devices used details  
 Listing 13: Successful deployment of endoprosthesis, failure details and additional procedure(s) conducted before/during the endovascular surgery  
 Listing 14: Imaging abnormalities observed following the procedure  
 Listing 15: False lumen perfusion following treatment for dissection  
 Listing 16: Persistent endoleak details following the procedure  
 Listing 17: Migrations details (deployment inaccuracy) identified following the procedure

###### *Follow-up*

Listing 18: Measurements and dissection characteristics – by visit  
 Listing 19: Imaging abnormalities observed – by visit  
 Listing 20: Dissection false lumen perfusion characteristics – by visit  
 Listing 21: Endoleak details – by visit  
 Listing 22: Migrations details – by visit

##### **Endpoints Analyses**

Listing 23: Primary and secondary endpoints

##### **Safety**

Listing 24: Secondary procedures  
 Listing 25: Adverse events

	<b>STATISTICAL ANALYSIS PLAN</b>	Gore-TAG_SAP_V2.2 TAG Registry Page 15/18
--	----------------------------------	---

## 5. LAYOUT OF THE STATISTICAL TABLES

### 5.1. Continuous variables

#### 5.1.1. No group (Type 1)

Variable	N	Missing	Mean	S.D.	Median	Min, Max	Q1-Q3	95% CI*
Variable label	XX	XX	XX,X	XX,X	XX,X	XX,X , XX,X	XX,X - XX,X	[XX,X ; XX,X]

\*If needed

#### 5.1.1. With groups (Type 2)

Variable	Group label	N	Missing	Mean	S.D.	Median	Min, Max	Q1-Q3	95% CI*
Variable label	Group 1	XX	XX	XX,X	XX,X	XX,X	XX,X , XX,X	XX,X - XX,X	[XX,X ; XX,X]
	Group 2	XX	XX	XX,X	XX,X	XX,X	XX,X , XX,X	XX,X - XX,X	[XX,X ; XX,X]
	...	...	...	...	...	...	...	...	...
	Group g	XX	XX	XX,X	XX,X	XX,X	XX,X , XX,X	XX,X - XX,X	[XX,X ; XX,X]
	Total*	XX	XX	XX,X	XX,X	XX,X	XX,X , XX,X	XX,X - XX,X	[XX,X ; XX,X]

\*If needed

### 5.2. Categorical variables

#### 5.2.1. No group (Type 3)

		Population (N=XX)
Variable label	N	XX
	Variable 1	XX (XX.X%)
	95% CI (Variable 1)*	[XX.X% - XX.X%]
	Variable 2	XX (XX.X%)
	95% CI (Variable 2)*	[XX.X% - XX.X%]
	...	...
	Variable n	XX (XX.X%)
	95% CI (Variable n)*	[XX.X% - XX.X%]
	Missing	XX

\*If needed

#### 5.2.2. With groups (Type 4)

		Group label				
		Group 1 (N=XX)	Group 2 (N=XX)	....	Group n (N=XX)	Total* (N=XX)
Variable label	N	XX	XX	...	XX	XX
	Variable 1	XX (XX.X%)	XX (XX.X%)	...	XX (XX.X%)	XX (XX.X%)
	95% CI (Variable 1)*	[XX.X% - XX.X%]	[XX.X% - XX.X%]	...	[XX.X% - XX.X%]	[XX.X% - XX.X%]
	Variable 2	XX (XX.X%)	XX (XX.X%)	...	XX (XX.X%)	XX (XX.X%)
	95% CI (Variable 2)*	[XX.X% - XX.X%]	[XX.X% - XX.X%]	...	[XX.X% - XX.X%]	[XX.X% - XX.X%]
	...	...	...	...	...	...
	Variable n	XX (XX.X%)	XX (XX.X%)	...	XX (XX.X%)	XX (XX.X%)
	95% CI (Variable n)*	[XX.X% - XX.X%]	[XX.X% - XX.X%]	...	[XX.X% - XX.X%]	[XX.X% - XX.X%]

**CONFIDENTIEL / CONFIDENTIAL**

Toute reproduction ou distribution, totale ou partielle, de ce document, sans autorisation préalable de MedPass International est interdite.  
Reproduction and distribution of this document, in whole or in part, is strictly forbidden without prior authorization from MedPass International.

	<b>STATISTICAL ANALYSIS PLAN</b>	Gore-TAG_SAP_V2.2 TAG Registry Page 16/18
--	----------------------------------	---

		Group label				
		Group 1 (N=XX)	Group 2 (N=XX)	....	Group n (N=XX)	Total* (N=XX)
	Missing	XX	XX	...	XX	XX

\*If needed

### 5.3. Others

#### 5.3.1. Several variables or variables with more than one modality by patient (Type 5)

Variable 1 / Variable 2	Population (N=XX)	95% CI
Variable 1 modality 1	XX (XX.X%)	[XX.X% - XX.X%]
Variable 1 modality 2	XX (XX.X%)	[XX.X% - XX.X%]
...	...	...
Variable 1 modality n	XX (XX.X%)	[XX.X% - XX.X%]

(sum of all modality ≥ total number of patient)

\*If needed

#### 5.3.2. Conditional variables (Type 6)

Variable 1 / Variable 2	Population (N=XX)	95% CI*
Variable 1 modality 1	XX (XX.X%)	XX (XX.X%)
Variable 2 modality 1	XX (XX.X%)	XX (XX.X%)
Variable 2 modality 2	XX (XX.X%)	XX (XX.X%)
...	...	...
Variable 2 modality n	XX (XX.X%)	XX (XX.X%)
Variable 1 modality 2	XX (XX.X%)	XX (XX.X%)
Variable 2 modality 1	XX (XX.X%)	XX (XX.X%)
Variable 2 modality 2	XX (XX.X%)	XX (XX.X%)
...	...	...
Variable 2 modality n	XX (XX.X%)	XX (XX.X%)
...	...	...
Variable 1 modality n	XX (XX.X%)	XX (XX.X%)
Variable 2 modality 1	XX (XX.X%)	XX (XX.X%)
Variable 2 modality 2	XX (XX.X%)	XX (XX.X%)
...	...	...
Variable 2 modality n	XX (XX.X%)	XX (XX.X%)

\*If needed

#### 5.3.1. Conditional variables with groups (Type 7)

Variable 1 / Variable 2	Group 1 (N=XX)	95% CI* (Group 1)	Group 2 (N=XX)	95% CI* (Group 2)	...	Group n (N=XX)	95% CI* (Group n)
Variable 1 modality 1	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	...	XX (XX.X%)	XX (XX.X%)
Variable 2 modality 1	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	...	XX (XX.X%)	XX (XX.X%)
Variable 2 modality 2	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	...	XX (XX.X%)	XX (XX.X%)
...	...	...	...	...	...	...	...

#### CONFIDENTIEL / CONFIDENTIAL

Toute reproduction ou distribution, totale ou partielle, de ce document, sans autorisation préalable de MedPass International est interdite.  
Reproduction and distribution of this document, in whole or in part, is strictly forbidden without prior authorization from MedPass International.

	<b>STATISTICAL ANALYSIS PLAN</b>	Gore-TAG_SAP_V2.2 TAG Registry Page 17/18
--	----------------------------------	---

Variable 1 / Variable 2	Group 1 (N=XX)	95% CI* (Group 1)	Group 2 (N=XX)	95% CI* (Group 2)	...	Group n (N=XX)	95% CI* (Group n)
Variable 2 modality n	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	...	XX (XX.X%)	XX (XX.X%)
Variable 1 modality 2	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	...	XX (XX.X%)	XX (XX.X%)
Variable 2 modality 1	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	...	XX (XX.X%)	XX (XX.X%)
Variable 2 modality 2	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	...	XX (XX.X%)	XX (XX.X%)
...	...	...	...	...	...	...	...
Variable 2 modality n	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	...	XX (XX.X%)	XX (XX.X%)
...	...	...	...	...	...	...	...
Variable 1 modality n	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	...	XX (XX.X%)	XX (XX.X%)
Variable 2 modality 1	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	...	XX (XX.X%)	XX (XX.X%)
Variable 2 modality 2	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	...	XX (XX.X%)	XX (XX.X%)
...	...	...	...	...	...	...	...
Variable 2 modality n	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	...	XX (XX.X%)	XX (XX.X%)

\*If needed

### 5.3.1. Adverse events (Type 8)

Adverse events	Population (N=XX)		
	NAE (1)	n (2)	% (3)
ALL	XX	XX	XX.X
Type 1	XX	XX	XX.X
Type 2	XX	XX	XX.X
...	...	...	...
Type n	XX	XX	XX.X


(1): Number of adverse events/medication of a given type of adverse event/medication

(2): Number of patients with at least one adverse event of a given type of adverse event

(3): (n / N)\*100 (N: total number of patients)

## STATISTICAL ANALYSIS PLAN

### 5.3.2. Survival curve (Type 9)



#### Summary table

	Mod 1 (n=X)	...*	Mod n* (n=X)	Log-Rank test
Nb of patients	X	...	X	
Nb of patients with an event	XX (XX.X%)	...	XX (XX.X%)	0.xxx
Nb of patients without an event	XX (XX.X%)	...	XX (XX.X%)	
Survival rate	XX%	...	XX%	
Progression-Free survival (days)		...		
Median	XX	...	XX	
(95% CI)	(XX.X, XX.X)	...	(XX.X, XX.X)	
25th-75th percentile	XX.X – XX.X	...	XX.X – XX.X	
Range	XX.X – XX.X	...	XX.X – XX.X	

\* If any

**CONFIDENTIEL / CONFIDENTIAL**

Toute reproduction ou distribution, totale ou partielle, de ce document, sans autorisation préalable de MedPass International est interdite.  
Reproduction and distribution of this document, in whole or in part, is strictly forbidden without prior authorization from MedPass International.